A wait and see approach for desmoid tumors (DT) has become part of the routine treatment strategy. However, predictive factors to select the risk of progressive disease are still lacking.
| INTRODUCTION
Desmoid tumors (DT) are rare mesenchymal diseases. Despite the complete absence of metastatic capacity, DT are very infiltrative with high local recurrence rates even after complete surgical resection. In recent years, as an alternative to mutilating surgery, patient surveillance (wait and see, W&S) has been routinely proposed as part of initial management. 1 In fact, long lasting stability and spontaneous regression are not infrequent events. 2 Unfortunately, there are no molecular or clinical predictors to guide clinicians in the daily practice, for promptly selecting patients for surgery/medical therapy or for continuous W&S. Recently, a potential prognostic value of β-catenin has been shown in two series of surgically treated patients. A specific mutation (S45F) had a worse outcome in terms of recurrence free survival. 3, 4 Moreover, the same mutation has been associated with a better response to Imatinib in patients with progressive disease. 5 In order to understand the natural history of this challenging disease, two prospective European clinical trials (NCT02547831; NCT01801176) will provide new data on the role of W&S.
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We conducted a parallel translational study on patients enrolled in the Italian observational study in order to possibly identify genome alterations that drive aggressive behavior and to look for predictive factors using a high throughput genome approach. The assumption is that progression (in patients "observed") and recurrence (in patients "operated") represents different faces of biological aggressiveness.
This could be useful in the future to personalize treatments according to the predicted aggressiveness of the disease in each patient from the beginning.
In recent years, high-throughput technologies such as nextgeneration sequencing (NGS) have been widely used to identify germline and somatic mutations or translocations in DNA that play a crucial role in cancer development and progression. In the last few years, many NGS-based studies have been carried out to provide a comprehensive molecular characterization of cancers, to identify novel genetic alterations contributing to tumorigenesis, cancer progression and metastasis, and to study tumor complexity and heterogeneity. 6 In fact, CTNNB1 WT tumors (determined by NGS) may have genomic alterations associated with Wnt activation (chromosome 6 loss/BMI1 mutation), supporting Wnt/bcatenin activation as the common pathway governing DT initiation.
Even though the majority of DT are karyotypically stable tumors, recurrent copy number alterations have been previously described, including loss of chromosome 5 and 6 in 5%-11% of cases and gain of chromosome 8 and 20 in a minority of patients. [7] [8] [9] [10] Loss of chromosome arm 5q, involving APC, was detected in tumors from both patients with and without FAP. 7 The meaning of these events in the pathogenesis of the disease has never been elucidated. The aim of this study was to characterize the molecular events beyond Wnt/beta catenin pathway in a prospectively enrolled patients under W&S and in a subgroup of DT samples assigned by Sanger sequencing to the WT subclass.
| MATERIALS AND METHODS

| Case selection
Twelve patients with primary sporadic naïve DT enrolled in the prospective study were included in this translational study. Recurrent, pre-treated and FAP patients were excluded. A specific informed consent was obtained. Patients, tumors and molecular data are listed in Table 1 . DT fresh frozen (FF) samples from enrolled patients who have been biopsied at our institution were collected for translational studies. Frozen samples and blood samples were available for the analysis.
In addition, 11 FFPE samples from patients previously operated for WT DT were analyzed. Patients, tumors and molecular data are listed in 
| Bioinformatic analysis
For WES data, after demultiplexing and FASTQ generation, the paired-end reads were trimmed using AdapterRemoval (https:// github.com/MikkelSchubert/adapterremoval) with the aim of removing stretches of low quality bases (<Q10) and adapters present in the sequences. washington.edu/EVS). In-depth evaluation of high confidence Variants were identified using somatic variant caller and annotated using Variant studio 3.0 (Illumina). Variants detected in only one strand were considered as FFPE artifacts and were excluded from the analysis.
| RNA extraction and reverse-transcription
RNA was extracted from FFPE samples using RecoverAll Total Nucleic Acid Isolation Kit (Thermo Fisher). RNA was quantified through UV absorbance. 500 ng of RNA was reverse-transcribed using SuperScript IV Reverse Transcriptase (Thermo Fisher) following manufacturer's instructions.
| PCR and Sanger sequencing
For APC large deletion detection, several primers covering the entire exon 15 were designed. LAMTOR2 sequencing was performed through Sanger sequencing, using primers covering the entire coding region of the gene. All PCR products were then purified and loaded onto an ABI 3730 Genetic Analyzer (Applied Biosystems, Monza, Italy)
for Sanger Sequencing. To screen for CTNNB1 intragenic deletions, several primers amplifying short fragments spanning the genomic region from exon 2 to exon 4 of CTNNB1 were designed. While for FF a single amplicon covering the entire region from exon 2 to exon 4 was generated and sequenced, to overcome the high degradation of FFPE samples several short amplicons were produced and screened for aberrant amplicon length or sequenced. All primers used are listed in Supporting Information, file 1. CTNNB1 mutant samples carried no recurrent mutational event.
However, few relevant private mutations could be detected, as a STOP gain mutation of SETDB1 (p.R495X) inW&S#11, and missense mutations in NRP2, RELN, LPA, EGR2 and PDX1, respectively, in W&S#1, #7, #2, #10, and #11 (Table 1) .
Of the two WT DT, W&S#6 harbored a complex alteration of APC involving a large deletion and acquisition of several somatic SNV.
In particular, sequencing of this case unveiled the presence of five somatic mutations in the same region of exon 15 of APC (Table 1) On the contrary, W&S#9 did not show any alterations of genes in the WNT pathway. However, of the mutations identified, a missense mutation (p.V92M) of LAMTOR2, a gene involved in mTORC1 activation, was detected and predicted as pathogenic by three bioinformatics tools (Table 1 and Supporting Information, file 2).
| Analysis of WT DT
To further characterize the molecular background of WT DT and to look for LAMTOR2 recurrent mutation in WT DT, FFPE tissues of 11 CTNNB1 WT DT surgically treated were collected and analyzed through NGS. (Table 2 and Supporting Information, file 3). Then, we attempted to perform WES on the surgically treated DT. However, due to low quality of FFPE DNA, we were able to synthetize WES libraries in only 6 out of 11 cases (three WT and three with low frequencies CTNNB1 mutations). Adjusting the filtering parameters of WES analysis, we validated the presence of low frequency mutation of CTNNB1 in the predicted three cases (data not shown).
| Identification of CTNNB1 intra-genic deletions
Since it is known that DT tumors could carry a variety of complex alterations in CTNNB1, including clonal mutations, we decided to further investigate CTNNB1 in WT cases, with the aim to detect all possible complex or cryptic mutational events.
Starting from WES data of the 6 FFPE cases (Table 2) was detected in the other allele.
| Expression of mutant CTNNB1
We then evaluated whether all these different types of alterations of CTNNB1 were actually expressed. RNA extracted from 5 cases of FFPE DT was reverse-transcribed, amplified, and sequenced with Sanger method. Peculiarly, in Surg#4 we were able to detect the expression of the deleted allele of CTNNB1 ( Figure 3A ) and we unveiled the effective CTNNB1 protein ( Figure 3B ). Finally, through cDNA sequencing of a low frequency CTNNB1 mutated sample (Surg#3), we demonstrated that the T41A allele, even if it was carried by only 15% of cells, was the prevalent allelic isoform expressed with respect to the WT allele ( Figure 3C ).
| DISCUSSION
Sporadic DT are characterized by a low load of mutational events, except for the major molecular alterations (exon 3 CTNNB1 mutation)
in the vast majority of cases. In this small series, the specific type of mutation did not seem to influence the clinical course: however, the two patients with CTNNB1 S45F mutation were shifted to an active treatment. This is a small-sized cohort and the results of the prospective European studies on a W&S approach will convey the results through an adequately powered series.
With the aim to better characterize DT, we analyzed a prospective cohort of patients going through W&S observational protocol.
Through whole exome sequencing, we confirmed the presence of specific CTNNB1 mutations in 10 patients, as already seen with Sanger sequencing. In the remaining two CTNNB1 WT samples, a complex APC mutation was discovered in one case and in the other no somatic alteration affecting WNT/CTNNB1 pathway was found. Two APC mutated cases were also detected among the 11 retrospective WT DT collected. Peculiarly all these mutations, together with the one seen in the W&S case, occurred in exon 15 of APC, according to the previous findings that indicated the 5 0 part of the gene as the most frequent target of mutation, especially in association with FAP disease. 11 APC is known to be affected by several types of mutation, from SNV to gross and complex insertions or deletions. Moreover, large submicroscopic deletions were reported in FAP patients. 11, 12 In this series, we detected a novel complex alteration of APC, composed of an intragenic deletion of part of exon 15 and the acquisition of 5 somatic mutations, adding a further layer of complexity in the characterization of APC mutational status.
In the W&S cohort, only one case could be considered a truly WT DT. In a recent paper, Crago et al. described for the first time the presence of CTNNB1 mutated cases with low mutant allele frequency not detectable by traditional sequencing and considered as WT DT. 6 In our retrospective series of WT DT, through deep sequencing technique we were able to detect CTNNB1 low frequency mutations in 5 out of 11 CTNNB1 WT cases (45%). Despite being low frequency mutations, we demonstrated that these events were prevalently expressed, and easier to be detected at the mRNA level, since the mutated allele of CTNNB1 was much more expressed than the WT allele. However, the pathogenetic relevance of this low load of CTNNB1 mutation needs further validation. We may speculate that it can represent a favorable evolution towards a spontaneous regression. In fact, the favorable course of WT DT was already shown in different retrospective series of patients treated with surgery supporting the fact that WT may have a more indolent course. 4, 13, 14 The two European prospective study will provide new insight on this hypothesis.
Interestingly, searching for complex mutational events occurring in CTNNB1, we discovered for the first time intra-genic deletions in DT. In particular, we unveiled the presence of two different large deletions, of about 190 bp, involving exon 3 of CTNNB1 in two DT cases. Moreover, we demonstrated that the deleted CTNNB1 was expressed and that it retained the coding frame for protein translation. Only few reports describing similar deletion of CTNNB1 in hepatoblastoma and in small bowel carcinomas are already present in literature. [15] [16] [17] Interestingly, these types of deletions could be of different lengths, from 24 to 660 bp, and they could encompass the region between exon 2 to exon 4 of CTNNB1. 16 Nevertheless, also in these other tumors, these intra-genic deletions were described to be in frame, leading to the production of an activated form of CTNNB1 that can localize to the nucleus. 17 Unfortunately, these types of deletions are hard to be detected by high throughput techniques, since they are too large for conventional NGS analysis pipelines and too small for CGH workflow. Moreover, working on fragmented DNA, as those extracted from FFPE tissue, it is not easy to perform a PCR screening of the region. Due to these limitations, we could not exclude that other deleted cases could be present in the retrospective cohort analyzed. Therefore, even if we have detected only 2 deleted cases, the frequency of these type of alterations could be higher, thus possibly contributing to explain at least a portion of the allegedly WT DT cases. Additionally, it must be noted that one of the CTNNB1 deleted cases carried also a low allele frequency T41A mutation suggesting a high level of heterogeneity in the tumor never described so far in DT.
In conclusion, novel molecular alterations in APC and CTNNB1
were identified. A minority of DT remained WT for either CTNNB1, APC or any other gene involved in the WNT pathway. Particular attention should be paid to the intra-genic deletions of CTNNB1 that, for the complexity of detection, could have been underestimated in DT until now. These molecular findings and their clinical meanings deserve further investigation in larger series.
